Euro Roundup: Notified bodies call for access to Eudamed to enable move to risk-based oversight
A medtech notified-bodies trade group, Team-NB, urged EU authorities to grant notified bodies access to Eudamed to support proposed risk-based surveillance under pending medical device reforms. Team-NB said current access is limited to certain modules and asked that EMA and notified bodies access all referenced systems. Separately, EDQM reactivated a botulinum toxin working party to phase out LD50 mouse testing.
How this was made
The 30-second read
Why it matters
For medtech, broader Eudamed access could streamline surveillance planning and reduce duplicated data gathering, but it is still tied to pending reforms and implementation details. For botulinum toxin products, phasing out LD50 testing could reduce animal-testing requirements over time, but the article does not confirm adoption dates or acceptance of specific alternatives. For MS drugmakers, EMA’s draft qualification could improve feasibility of post-authorization safety studies using registry data, potentially affecting evidence strategy for disease-modifying therapies.
Market read
This is a regulatory-process update with potential medium-term compliance and evidence-strategy implications for medtech and certain pharma products, but it lacks immediate, company-specific financial triggers.
What to watch
Actual market impact depends on whether notified bodies and manufacturers can practically use Eudamed modules, and whether botulinum toxin monograph revisions include clear timelines and acceptance criteria for alternative assays.
Background
The piece covers three EU/UK regulatory developments: (1) a request to expand notified bodies’ access to Eudamed for risk-based oversight, (2) EPC reactivating a botulinum toxin working party to phase out mouse LD50 testing, and (3) EMA consultation on a multiple sclerosis data network for PASS, plus an MHRA quarantine recommendation for nonconforming UK-supplied devices.
Ticker impact
The article links EU botulinum toxin LD50 testing to AbbVie’s Allergan Botox, implying potential regulatory and compliance cost changes.
Low near-term impact; any repricing would likely require follow-on implementation details or guidance affecting product compliance timelines.
The text describes a working-party roadmap and membership call, not an enacted rule or quantified cost/timeline change for AbbVie’s specific products.
Market effects
Medtech and pharma compliance workflows may shift toward risk-based surveillance with broader database access, potentially changing notified-body operating models and documentation burdens.
EU regulatory process changes and UK MHRA quarantine guidance can affect device supply chains and compliance costs across Europe.
Could influence global medtech regulatory harmonization efforts if EU risk-based oversight becomes a template for other jurisdictions.
Counterpoint
Database access and LD50 phase-out roadmaps may not translate into faster approvals or lower costs until legislation and implementing acts are finalized.
Key entities
- trade associationTeam-NB
Represents medtech notified bodies and argues notified bodies need access to Eudamed systems to enable risk-based oversight.
- regulatory databaseEudamed
EU medtech database; the article says notified bodies currently lack access to planned vigilance and clinical investigation modules.
- regulatory bodyEuropean Pharmacopoeia Commission (EPC)
Reactivated the Botulinum Toxin Working Party to develop a roadmap to phase out mouse LD50 testing in Ph. Eur. monographs.
- regulatory bodyEuropean Directorate for the Quality of Medicines and HealthCare (EDQM)
Supports the LD50 phase-out effort and issued related updates, including a new chapter on procoagulant activity testing in immunoglobulin preparations.
- regulatory agencyEuropean Medicines Agency (EMA)
Consults on a draft qualification opinion for the Big Multiple Sclerosis Data network for PASS use.
